Carnitine is a nutrient in the body that turns fat into energy. It is found in meat, dairy, and bread. Carnitine has been used to improve heart health, ease fatigue, and promote fitness. It can be taken as a pill or powder. It can also be injected into the bloodstream by a healthcare provider.
1,000 milligrams 1 to 3 times daily.
What Research Shows
- Chronic heart failure—likely to ease symptoms and improve heart function E1
- Depression—likely to reduce symptoms G1
- Diabetes—likely help control blood glucose H1-H2
- Intermittent Claudication—likely to improve walking ability M1-M2
- Obesity—likely to promote weight loss P1
- Osteoarthritis—likely to ease pain Q1
- Peripheral neuropathic pain—likely to provide small reductions in pain R1-R2
May Not Be Effective
Unlikely to Be Effective
Not Enough Data to Assess
Editorial process and description of evidence categories can be found at EBSCO NAT Editorial Process.
It is likely safe to take carnitine in small doses for a short time. Not enough studies have been done to say whether it is safe to take for a long period. It is also not known whether it is safe to take by women who are pregnant or breastfeeding.
Talk to your doctor about any supplements or therapy you would like to use. Some can interfere with treatment or make conditions worse.
A. Acute Myocardial Infarction
A1. DiNicolantonio JJ, Lavie CJ, et al. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clin Proc. 2013 Jun;88(6):544-551.
B. Attention Deficit Hyperactivity Disorder
B1. Sarris J, Kean J, et al. Complementary medicines (herbal and nutritional products) in the treatment of Attention Deficit Hyperactivity Disorder (ADHD): a systematic review of the evidence. Complement Ther Med. 2011 Aug;19(4):216-227.
C. Brain Ischemia
C1. Fedotova AV, Mironova OP, et al. [L-carnitine treatment patients with chronic cerebral ischemia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(5):48-53.
D. Cancer-Related Fatigue
D1. Marx W, Teleni L, et al. Efficacy and Effectiveness of Carnitine Supplementation for Cancer-Related Fatigue: A Systematic Literature Review and Meta-Analysis. Nutrients. 2017 Nov 7;9(11). pii: E1224.
E. E. Chronic Heart Failure
E1. Song X, Qu H, et al. Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis or Randomized Controlled Trials. Biomed Res Int. 2017:6274854.
F. F. Cognitive Function
F1. Chen N, Yang M, et al. L-carnitine for cognitive enhancement in people without cognitive impairment. Cochrane Database Syst Rev. 2017 Mar 26;3:CD009374.
G. G. Depression
G1. Vernoese N, Stubbs B, et al. Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis. Psychosom Med. 2018;80(2):154-159.
H. H. Diabetes
H1. Vidal-Casariego A, Burgo-Peláez R, et al. Metabolic effects of L-carnitine on type 2 diabetes mellitus: systematic review and meta-analysis. Exp Clin Endocrinol Diabetes. 2013;121(4):234-238.
H2. Xu Y, Jiang W, et al. L-carnitine treatment of insulin resistance: A systematic review and meta-analysis. Adv Clin Exp Med. 2017 Mar-Apr;26(2):333-338.
I. Fragile X Syndrome
I1. Rueda JR, Guillén V, et al. L-acetylcarnitine for treating fragile X syndrome. Cochrane Database Syst Rev. 2015 May 19;(5):CD010012.
J. J. Hemodialysis
J1. Yang SK, Xiao L, et al. Effect of L-carnitine therapy on patients in maintenance hemodialysis: a systematic review and meta-analysis. J Nephrol. 2014 Jun;27(3):317-329.
K. K. Hepatic Encephalopathy
K1. Martí-Carvajal AJ, Gluud C, et al. Acetyl-L-carnitine for patients with hepatic encephalopathy. Cochrane Database Syst Rev. 2019;1:CD011451.
L. L. Hyperthyroidism
L1. An JH, Kim YJ, et al. L-carnitine supplementation for the management of fatigue in patients with hyperthyroidism on levothyroxine treatment: a randomized, double-blind placebo-controlled trial. Enocr J. 2016;63(10):885-895.
M. M. Intermittent Claudication
M1. Delaney CL, Spark JI, et al. A systematic review to evaluate the effectiveness of carnitine supplementation in improving walking performance among individuals with intermittent claudication. Atherosclerosis. 2013 Jul;229(1):1-9.
M1. Brass EP, Koster D, et al. A systematic review and meta-analysis of propionyl-L-carnitine effects on exercise performance in patients with claudication. Vasc Med. 2013 Feb;18(1):3-12.
N. N. Kidney Disease
N1. Huang H, Song L, et al. Influence of L-carnitine supplementation on serum lipid profile in hemodialysis patients: a systematic review and meta-analysis. Kidney Blood Press Res. 2013;38(1):31-41.
N2. Chen Y, Abbate M, et al. L-Carnitine supplementation for adults with end-stage kidney disease requiring maintenance hemodialysis: a systematic review and meta-analysis. Am J Clin Nutr. 2014;99(2):408-422.
O. O. Multiple Sclerosis
O1. Tejani AM, Wasdell M, et al. Carnitine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2012 May 16;(5):CD007280.
P. P. Obesity
P1. Pooyandjoo M, Nouhi M, et al. The effect of (L-)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials. Obese Rev. 2016;17(10):970-976.
Q. Q. Osteoarthritis
Q. Liu X, Machado GC, et al. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018;52(3):167-175.
R. R. Peripheral Neuropathic Pain
R1. Li S, Li Q, at al. Acetyl-L-carnitine in the treatment of peripheral neuropathic pain: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2015;10(3):e0119479.
R2. Brami C, Bao T, et al. Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review. Crit Rev Oncol Hematol. 2016 Feb;98:325-334.
S. S. Valproic Acid Overdose
S1. Perrott J, Murphy NG, et al. L-carnitine for acute valproic acid overdose: a systematic review of published cases. Ann Pharmacother. 2010 Jul-Aug;44(7-8):1287-1293.
Last reviewed July 2019 by EBSCO NAT Review Board Eric Hurwitz, DC Last Updated: 4/14/2020